We hypothesized that the expression of FAP in advanced NSCLC patients might serve as a surrogate marker that can stratify PD-1 blockade-treated patients into groups that benefit from blockade treatment and those that do not. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.